125 related articles for article (PubMed ID: 22353201)
1. Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer.
Shoji T; Sonobe M; Sakai H; Fujinaga T; Sato T; Chen F; Miyahara R; Bando T; Wada H; Date H
Rev Recent Clin Trials; 2012 May; 7(2):167-72. PubMed ID: 22353201
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
3. Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
Shiroyama T; Kijima T; Komuta K; Yamamoto S; Minami S; Ogata Y; Okafuji K; Imamura F; Hirashima T; Tachibana I; Kawase I; Kumanogoh A
Cancer Chemother Pharmacol; 2012 Dec; 70(6):783-9. PubMed ID: 22960985
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
van Groeningen CJ; Peters GJ; Schornagel JH; Gall H; Noordhuis P; de Vries MJ; Turner SL; Swart MS; Pinedo HM; Hanauske AR; Giaccone G
J Clin Oncol; 2000 Jul; 18(14):2772-9. PubMed ID: 10894878
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
[TBL] [Abstract][Full Text] [Related]
8. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
[TBL] [Abstract][Full Text] [Related]
10. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
Yamamoto K; Imamura H; Furukawa H; Kishimoto T; Tanaka J; Oshiro R; Tatsuta M; Masutani S; Fukunaga M; Nakayama T; Takemoto H; Kondo M; Kamigaki S; Kawasaki T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1748-51. PubMed ID: 16315929
[TBL] [Abstract][Full Text] [Related]
11. S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
Ueda Y; Yamagishi H; Yamashita T; Itoh N; Itoi H; Shirasaka T; Ajani JA
Jpn J Clin Oncol; 2004 May; 34(5):282-6. PubMed ID: 15231865
[TBL] [Abstract][Full Text] [Related]
12. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301.
Okumura N; Soh J; Suzuki H; Nakata M; Fujiwara T; Nakamura H; Sonobe M; Fujinaga T; Kataoka K; Gemba K; Kataoka M; Hotta K; Yoshioka H; Matsuo K; Sakamoto J; Date H; Toyooka S
BMC Cancer; 2021 May; 21(1):506. PubMed ID: 33957881
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Fujitani K; Narahara H; Takiuchi H; Tsujinaka T; Satomi E; Gotoh M; Hirao M; Furukawa H; Taguchi T
Oncology; 2005; 69(5):414-20. PubMed ID: 16319513
[TBL] [Abstract][Full Text] [Related]
15. Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Jeung HC; Rha SY; Shin SJ; Ahn JB; Noh SH; Roh JK; Chung HC
Jpn J Clin Oncol; 2010 Jan; 40(1):29-35. PubMed ID: 19880858
[TBL] [Abstract][Full Text] [Related]
16. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Yamada Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
[TBL] [Abstract][Full Text] [Related]
17. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Booka E; Imamura CK; Takeuchi H; Hamamoto Y; Gomi D; Mizukami T; Ichiyama T; Tateishi K; Takahashi T; Kawakubo H; Soejima K; Boku N; Tanigawara Y; Kitagawa Y
Gastric Cancer; 2016 Jul; 19(3):876-86. PubMed ID: 26304171
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.
Kawahara M; Furuse K; Segawa Y; Yoshimori K; Matsui K; Kudoh S; Hasegawa K; Niitani H;
Br J Cancer; 2001 Sep; 85(7):939-43. PubMed ID: 11592762
[TBL] [Abstract][Full Text] [Related]
19. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
[TBL] [Abstract][Full Text] [Related]
20. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
Ichinose Y; Yoshimori K; Sakai H; Nakai Y; Sugiura T; Kawahara M; Niitani H
Clin Cancer Res; 2004 Dec; 10(23):7860-4. PubMed ID: 15585618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
